Autolus Therapeutics (6A3A) AI Stock Analysis
Autolus Therapeutics
(Frankfurt:6A3A)
No summary available
Autolus Therapeutics (6A3A) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 376.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 437
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 1.60
- Revenue Growth
- 272.71%
- EPS Growth
- -14.59%
- Country
- Germany
- Employees
- 752
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Autolus Therapeutics Business Overview & Revenue Model
Company Description
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene auto...
Autolus Therapeutics Earnings Call Summary
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Autolus upgraded full‑year AUCATZYL net product revenue guidance to $140–$150M (from a prior $120–$135M) after reporting Q2 net product revenue of $45.7M (Q1 $26.2M) and H1 revenue of $71.9M (close to last year’s full‑year launch total); gross margin stepped up to 55% in Q2 (from 6% in Q1 and negative in 2025) with a target mature ALL gross margin of 65–70% within ~12–18 months, Q2 cost of sales was $20.5M, R&D $27.9M, SG&A $41.2M, loss from operations $43.8M and net loss $39.1M (vs. $61.2M and $47.9M in Q2 2025); cash and marketable securities were $201.6M at June 30 (excluding a July $75M initial draw under a $250M facility with an extra $25M available for 6 months and up to $150M contingent tranches), and combined with anticipated net revenues plus the first two tranches (~$100M) the company expects runway into Q2 2028; commercial footprint is >80 U.S. centers (projected 90+ by year‑end) and ~20 U.K. centers by year‑end; key near‑term catalysts include CARLYSLE (ACR year‑end), FELIX analyses and AUTO8 initial data by year‑end, BOBCAT first 12‑patient data in Q1 2027 and 18‑patient readout H2 2027, CATULUS pediatric enrollment completion by end‑2027 with pivotal data by end‑2027 and potential filing end‑2027/early‑2028, and LUMINA Phase II data in 2028.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 88 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksAutolus Therapeutics Peers Comparison
Overall Rating
FATE52Neutral
ALLO51Neutral
IPSC45Neutral
NKTX40Underperform
ARTV37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FATE | 52Neutral | $240.84M | -1.94 | -65.08% | ― | -23.36% | 27.52% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ALLO | 51Neutral | $376.59M | -1.67 | -50.04% | ― | ― | 40.16% |
| IPSC | 45Neutral | $267.99M | -1.46 | -52.76% | ― | -100.00% | -219.52% |
| NKTX | 40Underperform | $108.87M | -0.97 | -39.64% | ― | ― | -6.70% |
| ARTV | 37Underperform | $204.85M | -1.27 | -53.86% | ― | ― | -7.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:6A3A | Autolus Therapeutics | 1.31 | 0.10 | 8.26% | |
| FATE | Fate Therapeutics Inc | 2.04 | 0.95 | 87.16% | |
| ALLO | Allogene Therapeutics | 1.12 | 0.01 | 0.90% | |
| NKTX | Nkarta, Inc. | 1.53 | -0.42 | -21.54% | |
| IPSC | Century Therapeutics, Inc. | 1.52 | 0.96 | 171.91% | |
| ARTV | Artiva Biotherapeutics, Inc. | 4.20 | 0.76 | 22.09% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.